Tempest Therapeutics Inc. (TPST)
NASDAQ: TPST
· Real-Time Price · USD
10.15
-0.13 (-1.26%)
At close: Oct 01, 2025, 3:59 PM
10.40
2.46%
Pre-market: Oct 02, 2025, 08:50 AM EDT
-1.26% (1D)
| Bid | 9.9 |
| Market Cap | 45.07M |
| Revenue (ttm) | 486K |
| Net Income (ttm) | -43.1M |
| EPS (ttm) | -15.99 |
| PE Ratio (ttm) | -0.63 |
| Forward PE | -0.64 |
| Analyst | Hold |
| Dividends | n/a |
| Ask | 10.48 |
| Volume | 32,569 |
| Avg. Volume (20D) | 74,853 |
| Open | 10.27 |
| Previous Close | 10.28 |
| Day's Range | 10.09 - 10.49 |
| 52-Week Range | 5.36 - 20.67 |
| Beta | -2.29 |
| Ex-Dividend Date | n/a |
About TPST
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol TPST
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for TPST stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts3 months ago
-15.88%
Tempest Therapeutics shares are trading lower afte...
Unlock content with
Pro Subscription
3 months ago
+15.07%
Tempest Therapeutics shares are trading higher after the company announced it received orphan drug designation from the EMA for its amezalpat for the treatment of patients with hepatocellular carcinoma
